H.C. Wainwright analyst Robert Burns raised the firm’s price target on Exelixis (EXEL) to $49 from $46 and keeps a Buy rating on the shares following the Q3 report. The firm sees the key value driver for the shares as sentiment on the commercial future for zanzalintinib across various tumor types.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis price target raised to $51 from $44 at TD Cowen
- Exelixis price target raised to $43 from $41 at Stifel
- Exelixis price target raised to $41 from $40 at Barclays
- Exelixis’s Strong Financial Performance and Growth Prospects Earns Buy Rating from Yaron Werber
- Exelixis Reports Strong Q3 2025 Financial Results